2024-12-18 - Analysis Report
## Merck & Co Inc (MRK) Stock Report

**1. Performance Comparison & Overview:**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  Over the reviewed period, MRK's cumulative return (65.7%) significantly underperformed the S&P 500 (VOO) cumulative return (120.8%). The difference is -55.1%, placing it at the 7.7th percentile of the historical range (-63.7% to 48.6%).  This indicates that MRK's performance lagged behind the broader market.

The provided alpha consistently shows negative values (-0.1), indicating underperformance relative to the market benchmark. The beta fluctuates significantly, suggesting varying levels of market sensitivity over the years. Market capitalization (Cap(B)) shows a general upward trend.


**2. Recent Price Movement:**

* **Closing Price:** $100.06
* **5-Day Moving Average:** $100.14
* **20-Day Moving Average:** $100.22
* **60-Day Moving Average:** $103.79

The price is currently trading slightly below all three moving averages, suggesting a potential short-term downtrend.

**3. Technical Indicators & Expected Return:**

* **RSI (47.7):**  Suggests the stock is neither overbought nor oversold, remaining in neutral territory.
* **PPO (0.15):** A positive value indicates bullish momentum, although relatively weak.
* **20-Day Relative Divergence (-0.6):** Shows a recent slight downward trend in relative performance.
* **Expected Return (0.0%):**  The provided data indicates no expected excess return relative to the S&P 500 over the long term (2+ years).  This is likely based on historical data and doesn't account for future market shifts or company-specific events.  A 0% expected return doesn't mean no return at all, just no *additional* return compared to the S&P 500.

**4. Recent Earnings Analysis:**

The provided earnings data reveals some inconsistencies (duplicate entry for 2024-11-06).  Focusing solely on unique entries and observable trends:


* **Quarterly Revenue:** Shows a general upward trend, although growth has slowed slightly in recent quarters.
* **EPS:**  Fluctuates, without a clear upward or downward trend. A significant drop is observed between Q2 2024 and Q3 2024.
* **Comparison:**  Direct comparison to expectations is impossible without knowing those expectations.  The provided data shows actual reported numbers only.


**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue shows growth, but the profit margin shows a slight downward trend, suggesting increasing costs or reduced efficiency.
* **Capital and Profitability:** Equity has generally increased, but ROE is highly volatile, even showing a negative value in Q4 2023. This instability signals potential concerns regarding profitability consistency.

**6. News and Recent Issues:**

No recent news (within the last two days) or analyst opinions are provided.  Market outlook and specific performance highlights are also missing.  This crucial information would significantly impact the overall analysis.

**7.  Overall Analysis:**

MRK has significantly underperformed the S&P 500 over the provided historical period. While recent revenue growth is positive, the inconsistent EPS, fluctuating profitability metrics (ROE, profit margin), and lack of positive technical indicators (RSI, PPO)  paint a mixed picture. The absence of recent news and analyst opinions hinders a more definitive conclusion.  The 0% expected return suggests that, based on the provided historical data, investing in MRK is not expected to yield a greater return than a broad market index fund such as the S&P 500 over the long term. More up-to-date information (particularly recent news, market outlook, and analyst opinions) is crucial for a comprehensive assessment.


**8. Disclaimer:** This report is based solely on the limited data provided.  It does not constitute financial advice.  Independent research and consideration of additional information are essential before making any investment decisions.
